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Study ID Participants (n) Inclusion criteria Experimental intervention Definition of renal outcome Follow-up
Antimicrobials (PV=penicillin V, CA= cefuroxime axetil) for prevention of APSGN
Adam 2000 [14] 2264 Culture-proven 
tonsillo-pharyngitis
A) CA 20 mg/kg/d × 5 d
B) PV 50,000 IU/kg × 10 d
Glomerulonephritis 6–12 m
Adam 2000 [16] 4171 Age 1–18 y, clinical and 
laboratory diagnosis of 
tonsillo-pharyngitis
A)  (Amoxicillin/ clavulanate 37.5 
mg/kg/d or ceftibuten 9 mg/kg/d 
or CA 20 mg/kg/d or loracarbef 
15 mg/kg/d or clarithromycin 
15 mg/kg/d or erythromycin 40 
mg/kg/d) × 5 d
B) Oral PV 50,000 IU/kg/d × 10 d
Glomerulonephritis 12 m
Adam 2001 [15] 2099 Age 1–18 y, culture-proven 
streptococcal 
tonsillo-pharyngitis
A) Ceftibuten 9 mg/kg × 5 d
B) PV 50,000 IU/kg × 10 d
Glomerulonephritis 7–8 w
Scholz 2004 [17] 1952 Age 1–17 y, 
tonsillo-pharyngitis
A) CA 20 mg/kg/d × 5 d
B) PV 50,000 IU/kg × 10 d
Glomerulonephritis 1 y
Treatment of hypertension in APSGN
Ribeiro 1992 [18] 30 Age 3–11 y, clinical and 
laboratory diagnosis







20 Age 4–14 y A)  Furosemide 1–8.5 mg/kg/d, 
fractioned from 1 to 3 doses per os
B) reserpine 0.07 mg/kg, 2–3 times
1. Blood pressure
2. Diuresis 1–4 d
Morsi 1992 [19] 20 Age 4–10 y, 
hypertension
A)  Captopril 0.2 mg/kg, maintenance 
1.5 mg/kg/d






51 Age 3–16 y, acute tonsillo-
pharyngitis, impetigo, 
acute nephritic syndrome, 
urine changes of APSGN
A)  Enalapril 5-10 mg (6 weeks)
B)  β-blockers, vasodilators, diuretics 
and central acting agents (given 
if needed)
1. Blood pressure
2.  Echocardiographic 
changes 6–8 w
Treatment of crescentic glomerulonephritis from APSGN
Roy 1981 (21) 10 Age 5–16 y, 
comparable crescentic 
glomerulonephritis at renal 
biopsy
A)  Prednisone (1 mg/kg/d), 
azathioprine (1 mg/kg/d), 
cyclophosphamide (1 mg/kg/d), 
dipyridamole (10 mg/kg/d) for 3 







Table 1. Intervention in acute poststreptococcal glomerulonephritis: studies included in the systematic review.
d – day; h – hour; m – month; w – week; y – year.
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Study ID Participants (n) Inclusion criteria
Experimental 
intervention









A)  Furosemide 20 mg 
every 6 h
B)  PV 4,000,000 IU, 




24 hours Blood pressure 
reduction (DBP 82.4 
vs. 85.5) and diuresis 




16 Age 4–12 y A) furosemide (2 mg/kg)







I.  Shorter hypertension 
(mean: 4.7 range: 2–9 
d) vs. controls (mean: 
11.0 range: 7–20 d)
II.  Faster edema-free 
(6.8, range: 4–12 d) 
vs. controls (13.9, 
range: 6–23 d)
Table 2. Intervention in acute poststreptococcal glomerulonephritis: studies excluded from the analysis.
d – day; m – month; y – year.
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